Oculis (OCS) Competitors

Oculis (NASDAQ:OCS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Which has higher valuation and earnings, OCS or PTGX?

Protagonist Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$980K	876.80	-$98.92M	-$2.64	-7.45
Protagonist Therapeutics	$207.80M	16.80	-$78.96M	$0.75	75.09

Do institutionals and insiders hold more shares of OCS or PTGX?

22.3% of Oculis shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community believe in OCS or PTGX?

Protagonist Therapeutics received 259 more outperform votes than Oculis when rated by MarketBeat users. However, 91.89% of users gave Oculis an outperform vote while only 61.55% of users gave Protagonist Therapeutics an outperform vote.

Company	Underperform	Outperform
Oculis	Outperform Votes 34 91.89%	Underperform Votes 3 8.11%
Protagonist Therapeutics	Outperform Votes 293 61.55%	Underperform Votes 183 38.45%

Which has more risk & volatility, OCS or PTGX?

Oculis has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.

Does the media favor OCS or PTGX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 7 mentions for Oculis. Protagonist Therapeutics' average media sentiment score of 0.76 beat Oculis' score of -0.11 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer OCS or PTGX?

Oculis currently has a consensus target price of $35.33, suggesting a potential upside of 79.54%. Protagonist Therapeutics has a consensus target price of $65.44, suggesting a potential upside of 16.20%. Given Oculis' higher probable upside, equities research analysts clearly believe Oculis is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is OCS or PTGX more profitable?

Protagonist Therapeutics has a net margin of 52.76% compared to Oculis' net margin of -8,043.28%. Protagonist Therapeutics' return on equity of 34.68% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,043.28%	-71.31%	-56.85%
Protagonist Therapeutics	52.76%	34.68%	30.98%

Summary

Protagonist Therapeutics beats Oculis on 15 of the 18 factors compared between the two stocks.